CLINICAL TRIALS PROFILE FOR COLCRYS
✉ Email this page to a colleague
All Clinical Trials for Colcrys
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01001052 ↗ | Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2009-10-01 | The purpose of this study is to evaluate and compare the relative bioavailability of a single dose of Colcrys™ (colchicine) 0.6 mg when administered to a group of young , healthy subjects 18-30 years of age compared to a group of older, generally healthy subjects 60 years of age or older following an overnight fast. |
| NCT01084278 ↗ | Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) | Completed | Takeda | Phase 4 | 2010-05-01 | The primary objective of this study is to compare the pharmacokinetic profiles of colchicine and its primary metabolites in plasma and urine following a single 0.6 mg oral dose of colchicine in healthy adults with normal renal function, in patients with mild, moderate or severe renal impairment, and in patients with end-stage renal disease on hemodialysis. An additional objective of this study is to study the clearance of colchicine and its metabolites by hemodialysis. Secondary objectives include evaluation of the safety and tolerability of colchicine in the study population. |
| NCT01112982 ↗ | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 4 | 2010-05-01 | The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks. Secondary end-points of this study will include analyzing the effects of uric acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a subgroup of patients, checking for the presence of inflammatory markers to see if there is any correlation with the proposed chronic inflammation, and evaluating for other characteristic findings of gout on MRI. |
| NCT01112982 ↗ | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. | Completed | University of South Florida | Phase 4 | 2010-05-01 | The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks. Secondary end-points of this study will include analyzing the effects of uric acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a subgroup of patients, checking for the presence of inflammatory markers to see if there is any correlation with the proposed chronic inflammation, and evaluating for other characteristic findings of gout on MRI. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Colcrys
Condition Name
Clinical Trial Locations for Colcrys
Trials by Country
Clinical Trial Progress for Colcrys
Clinical Trial Phase
Clinical Trial Sponsors for Colcrys
Sponsor Name
